Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer

Abstract

We have investigated the influence of CCND1 genotype on clinical outcome in 138 women with epithelial ovarian cancer. CCND1 genotypes were identified from peripheral blood DNA by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis. Patient CCND1 genotypes were compared with clinical details including FIGO tumor stage, residual tumor volume, tumor histology and differentiation, response to chemotherapy, progression free interval, and survival. We observed no association between patient CCND1 genotypes and tumor characteristics or response to chemotherapy. There was no significant difference in overall survival and progression free interval (PFI) among women with different CCND1 genotypes. However, analysis of data from patients who responded to postoperative chemotherapy revealed that women with CCND1 AA genotype were associated with early disease progression (P = 0.020, HR 4.58, 95% CI 1.27-16.48) and reduced survival (P = 0.026, HR 4.48, 95% CI 1.19-16.79) compared with those with CCND1 AG and GG genotypes. These data show that CCND1 genotype does not influence overall prognosis in a cohort of epithelial ovarian cancer patients, however, it is associated with disease progression in a subgroup of patients following initial response to chemotherapy.

Cyclin D1 Gene G870A Variants and Primary Brain Tumors

“…However, findings are contradictory. Some of these studies indicated the association of CCDN1 G870A with cancer risk, prognosis, survival or characteristics of tumors such as larynx and oral cavity (Izzo, 2003), nonsmall lung cancer (Betticher et al, 1995), breast cancer (Yaylim-Eraltan et al, 2009), head and neck cancer (Zheng et al, 2001), ovarian cancer (Dhar et al, 1999), pituitary adenomas (Simpson et al, 2001). A meta-analysis which also includes our previous study (Yaylim-Eraltan et al, 2010), reported a significant association between colorectal cancer risk and G870A polymorphism.…”

CCND1 G870A polymorphism and cervical cancer risk: a case–control study and meta-analysis

“…Ceschi et al (2005) observed that the heterozygous AG genotype significantly reduces the risk for breast cancer compared with the GG genotype; this association, however, was restricted to women with high intake of n-6 fatty acids, low intake of antagonistic marine n-3 fatty acids, or a total lack of the antioxidative GSTM1. Dhar et al (1999) showed that CCND1 polymorphism influenced disease progression and altered survival in a small subgroup of patients with epithelial ovarian cancer who initially responded to postoperative chemotherapy. Also, Kang et al (2005) observed that the CCND1 polymorphism was associated with an increased risk for endometrial cancer.…”

“…The common G870A polymorphism in exon 4 of CCND1 modulates the frequency of alternative splicing and likely reduces transcript levels (Betticher et al 1995). Recent studies have shown that the G870A polymorphism is associated with elevated risks for breast, ovarian, and endometrial cancer (Ceschi et al 2005;Dhar et al 1999;Kang et al 2005). Also, several molecular epidemiological studies have examined the association between the G870A polymorphism of CCND1 and cervical cancer risk (Catarino et al 2008;Catarino et al 2005;Satinder et al 2008;Jeon et al 2005;Thakur et al 2009), but their results were inconclusive.…”

Cyclin D1 Pro241Pro (CCND1-G870A) Polymorphism Is Associated with Increased Cancer Risk in Human Populations: A Meta-Analysis

“…Heterogeneity was explored using subgroup analysis (10) with ethnicity (Asians and Caucasians) and cancer types. We have classified the cancer types in nine different categories including breast (13)(14)(15)(16)(17)(18)(19), colorectal (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34), gynecologic [ovarian (35), cervical (36), and endometrial (37)], digestive tract [oral (38)(39)(40), esophageal (41)(42)(43)(44), and stomach (45,46)], blood-related [acute lymphoblastic leukemia (47), mantle cell lymphoma (48), and non-Hodgkin's lymphoma (49)], genitourinary [bladder (50)(51)(52)(53), prostate (54,55), and kidney (56)], lung (57)(58)(59)…”